Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SURE: Short intensive treatment for children with tuberculous meningitis
ISRCTN40829906Phase 3Completed
- Sponsor
- University College London
- Start
- Jan 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of rifampicin, isoniazid, pyrazinamide, ethambutol, levofloxacin and 1 more in meningeal tuberculosis (4 arms), sponsored by University College London. Primary endpoints: All-cause mortality at 48 weeks and Neurodevelopment at 48 weeks. Started Jan 2020; status: completed.
02
Drugs
rifampicinisoniazidpyrazinamideethambutollevofloxacin
03
Conditions
meningeal tuberculosis
Beyond the preview
Go deeper on ISRCTN40829906.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN40829906.